Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature

Goto, Taichiro

doi:10.3390/cancers10070223

Cited by 26 publications

(20 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…165 A pertinent issue with regard to oncologic management is the risk of acute exacerbation of the underlying ILD, with an incidence of 21.4% in one study of CTD-ILD patients. 164 Both chemotherapy and thoracic surgery can cause an acute exacerbation in ILD patients 167,168 and radiotherapy is associated with the risk of radiation pneumonitis. 164,169 The infectious complications of chemotherapy can also be challenging in patients who have required immunosuppression for their lung disease.…”

Section: Malignancy In Ssc-ildmentioning

confidence: 99%

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview

Mackintosh

Stainer

Barnett

et al. 2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc). SSc-ILD adversely impacts quality of life and is currently the leading cause of death in this multisystem disease. Identifying clinically significant SSc-ILD is critically important. Accurate staging and prognostication remain difficult; however, significant advances have been made in the last decade. Evidence supports the need to treat patients with extensive and/or progressive SSc-ILD, while only a subset of patients with limited ILD may require treatment. Research is urgently required to allow improved prediction of patients at risk of ILD progression at an early point in the disease, and ideally prior to its onset, to allow prevention. The last decade has seen the publication of landmark clinical trials for SSc-ILD. More effective strategies with less toxicity are under investigation. For those with refractory or very advanced disease, studies into disease-specific palliative approaches are in their infancy. Lung transplantation as an option for SSc-ILD remains patient- and center-specific, with data to suggest equivalent outcomes to other fibrotic lung diseases, in carefully selected cases. This review aims to provide a comprehensive overview of all key aspects of SSc-ILD.

show abstract

Section: Malignancy In Ssc-ildmentioning

confidence: 99%

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview

Mackintosh

Stainer

Barnett

et al. 2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…The DL CO test was mainly missed in patients without underlying lung fibrosis and respiratory symptoms before surgery. Nevertheless, since DL CO has been reported as a risk factor for postoperative respiratory complication, patients with a low DL CO should be carefully evaluated, particularly for surgery-related AE-IPF or ARDS [33]. This study had several limitations.…”

Section: Plos Onementioning

confidence: 94%

Impact of idiopathic pulmonary fibrosis on recurrence after surgical treatment for stage I–III non-small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Background Idiopathic pulmonary fibrosis (IPF) is an independent risk factor for lung cancer (LC) development; however, its effect on recurrence after curative surgery remains unclear. Objectives This study aimed to determine the impact of IPF on recurrence-free survival following curative surgical resection of stage I-III non-small cell lung cancer (NSCLC) and investigate the effects of patient and surgical factors on the risk of recurrence. Methods We reviewed retrospectively collected data of patients with surgically resected stage I-III NSCLC from two tertiary care hospitals in South Korea. By propensity score matching, patients with IPF (LC with IPF) were matched to those without IPF (LC without IPF). Results In total, 3416 patients underwent surgical resection, and 96 were diagnosed with underlying IPF. In the LC with IPF group, 89.6% patients were men, and the average age was 69.7 years. Sublobar resection was performed more frequently in the LC with IPF group than in the LC without IPF group, while the rate of mediastinal lymph node dissection and dissected node number were lower in the former group. The 5-year recurrence-free survival rate was significantly lower in the LC with IPF group (49.2%) than in the LC without IPF group (69.1%; P<0.001). Multivariable Cox regression analysis revealed that IPF and postoperative stage III were independent risk factors for recurrence.

show abstract

“…Recent studies have demonstrated that the lung microbiome is also associated with the pathogenesis of IPF (Table 2) [48,[57][58][59][60]. Analysis of BAL samples from patients with interstitial pneumonia, including idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia, and acute interstitial pneumonia, resulted in the detection of classic respiratory pathogens such as Haemophilus influenzae and various other pathogens that are rarely detected [61].…”

Section: Lung Microbiome and Idiopathic Pulmonary Fibrosis (Ipf)mentioning

confidence: 99%

Airway Microbiota as a Modulator of Lung Cancer

Goto

2020

IJMS

Self Cite

View full text Add to dashboard Cite

Recent research on cancer-associated microbial communities has elucidated the interplay between bacteria, immune cells, and tumor cells; the bacterial pathways involved in the induction of carcinogenesis; and their clinical significance. Although accumulating evidence shows that a dysbiotic condition is associated with lung carcinogenesis, the underlying mechanisms remain unclear. Microorganisms possibly trigger tumor initiation and progression, presumably via the production of bacterial toxins and other pro-inflammatory factors. The purpose of this review is to discuss the basic role of the airway microbiome in carcinogenesis and the underlying molecular mechanisms, with the aim of developing anticancer strategies involving the airway microbiota. In addition, the mechanisms via which the microbiome acts as a modulator of immunotherapies in lung cancer are summarized.

show abstract

Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature

Cited by 26 publications

References 61 publications

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview

Impact of idiopathic pulmonary fibrosis on recurrence after surgical treatment for stage I–III non-small cell lung cancer

Airway Microbiota as a Modulator of Lung Cancer

Contact Info

Product

Resources

About